About US
Contact us
-
Bristol-Myers' Opdivo-Yervoy cocktail slashes kidney cancer death risk by 37%MADRID, Spain—Bristol-Myers Squibb smashed doubt about Opdivo and Yervoy’s utility in first-line kidney cancer on Sunday with data showing patients lived longer when treated up front with the combo, r2017/9/11
-
ESMO: Lilly pads case for third-to-market abemaciclib with more positive breast cancer dataMADRID, Spain—Eli Lilly is gearing up to challenge Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negativebreast cancer, and it rolled out more positive data for candidate abemaciclib ove2017/9/11
-
Champions Oncology to collaborate with ALCMI to develop new cohort of PDX modelsChampions Oncology has entered into a collaboration deal with the Addario Lung Cancer Medical Institute (ALCMI) to develop a new cohort of PDX models in patients with ROS1 gene rearrangement. These m2017/9/8
-
US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitisThe US Food and Drug Administration (FDA) has accepted for filing Pfizer’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate), an investigational oral solution to treat adult p2017/9/8
-
Glenmark secures UK MHRA approval for anti-malarial medicationGlenmark Pharmaceuticals Europe (Glenmark)has securedfinal approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Maloff Protect, its range ofatovaquone / proguanil film-c2017/9/7
-
Synlogic completes first phase in ongoing R&D collaboration with AbbVieUS-based pharmaceutical firm Synlogic has met the first discovery milestone in its ongoing research and development (R&D) collaboration with AbbVie. In the completed first discovery phase, Synlog2017/9/7
-
Roivant forms new subsidiary to develop urology therapiesHealthcare firm Roivant Sciences has formed a new subsidiary known as ‘Urovant Sciences’ to develop new therapies for addressing urologic conditions. Urovant has licensed global rights, except in cer2017/9/6
-
Lundbeck secures rights to IBC's research for Alzheimer's treatmentDanish pharmaceutical company Lundbeck has signed an agreement to secure the rights of biotech firm ImmunoBrain Checkpoint’s (IBC) breakthrough research in Alzheimer's disease treatment. The research2017/9/6
-
Merck and F-star to develop five bispecific immuno-oncology antibodiesGerman science and technology firm Merck has entered a new strategic collaboration with UK-based biopharmaceutical firm F-star to develop and commercialise five bispecific immuno-oncology antibodies.2017/9/5
-
Novartis and IBM Watson to optimise cancer care and patient outcomesNovartis has partnered with IBM Watson Health on an outcome-based initiative for patients with advanced breast cancer. The collaboration will involve research on a cognitive solution that uses real-w2017/9/5